Effectiveness of Musicotherapy in Reducing Pain Induced by Leg Ulcer Care

NCT ID: NCT06153589

Last Updated: 2025-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-08

Study Completion Date

2026-09-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Venous leg ulcer is the final stage of chronic venous disease and only develops due to advanced chronic venous insufficiency. The problems caused by venous disease are initially minor and often neglected, but can impact the quality of life of patients.

The prevalence of leg ulcers is estimated at 1% of the general population and 3% to 5% of subjects over 65 years old. Its prevalence increases with age in both men and women.

Managing chronic ulcers requires a certain number of care procedures, including debridement.

The act of treatment by mechanical debridement is little relieved by the analgesics given beforehand, and can be painful, with risks of bleeding.

Musicotherapy, particularly the U-shaped method, has shown its effectiveness in the treatment of pain and anxiety in several areas (geriatrics, intensive care, rheumatology, oncology, etc.).

The standardized musicotherapy method of the U-shaped sequence was developed and initially evaluated by clinical studies coordinated by the INSERM unit U1061 (Pr. Jacques Touchon; Dr. Stéphane Guétin).

Following the publication of numerous controlled, randomized studies presenting results on the effectiveness in the treatment of pain and anxiety, a digital application was developed in order to standardize the method. The Music Care health application is now a Class 1 Medical Device, with CE marking obtained.

This "U-shaped sequence" is standardized and has been clinically validated, which makes Music Care a unique tool available for pain relief.

No studies have been found in the literature regarding the use of music therapy during debridement care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Debridement Care Leg Ulcer Leg Ulcers Venous Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Debridement Venous leg ulcer Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Musicotherapy + debridement and usual analgesic protocol

Patients in the experimental arm will receive classic debridement care and usual use of analgesic treatment, accompanied by a musicotherapy session respecting the standardized method of the U-shaped sequence.

Group Type EXPERIMENTAL

Musicotherapy

Intervention Type OTHER

Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.

Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.

The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.

The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement.

Debridement and usual analgesic protocol

Patients in the experimental arm will receive classic debridement care and usual use of analgesic treatment.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Musicotherapy

Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.

Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.

The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.

The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient,
* Patient followed at the M@diCICAT healing center requiring wound debridement :

* For a venous or arterial ulcer or necrotizing angiodermatitis of the lower limbs,
* Having the ability to verbalize about their pain (communicating),
* With a planned debridement time of less than 40 minutes.
* Patient affiliated to or beneficiary of a social security scheme,
* Patient having given free, informed and express consent.

Exclusion Criteria

* Patient with a diabetic foot (loss of sensitivity-neuropathy),
* Patient not requiring a debridement session,
* Patient with an infected ulcer (abscess, etc.),
* Patient with critical ischemia,
* Patient with hearing problems,
* Patient with cognitive disorders,
* Patient placed under legal protection, guardianship or curatorship,
* Pregnant or breastfeeding woman.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Music Care

UNKNOWN

Sponsor Role collaborator

University Hospital Center of Martinique

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emmanuelle Guitteaud

Role: PRINCIPAL_INVESTIGATOR

University Hospital Center of Martinique

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Center of Martinique

Fort-de-France, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emmanuelle Guitteaud

Role: CONTACT

Phone: 05 96 55 35 45

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yann Mopsus, MSc

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

23_RIPH2-10

Identifier Type: -

Identifier Source: org_study_id